908 Devices (NASDAQ:MASS - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.
A number of other analysts have also recently weighed in on the company. Leerink Partners raised 908 Devices from a "market perform" rating to an "outperform" rating and set a $12.00 price target for the company in a research report on Tuesday, August 5th. Wall Street Zen raised 908 Devices from a "sell" rating to a "hold" rating in a research report on Monday, September 15th. Finally, Leerink Partnrs raised 908 Devices from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $8.00.
Check Out Our Latest Analysis on 908 Devices
908 Devices Trading Up 1.1%
NASDAQ MASS traded up $0.10 on Wednesday, reaching $9.01. The stock had a trading volume of 108,070 shares, compared to its average volume of 1,327,625. The business has a 50 day moving average price of $6.76 and a 200 day moving average price of $6.09. 908 Devices has a 1 year low of $1.81 and a 1 year high of $9.19. The company has a market capitalization of $322.92 million, a price-to-earnings ratio of -16.68 and a beta of 0.46.
908 Devices (NASDAQ:MASS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.02). 908 Devices had a negative net margin of 30.54% and a negative return on equity of 24.30%. The firm had revenue of $4.70 million during the quarter, compared to analysts' expectations of $12.17 million. 908 Devices has set its FY 2025 guidance at EPS. On average, analysts anticipate that 908 Devices will post -1.99 earnings per share for the current fiscal year.
Insider Buying and Selling
In other 908 Devices news, CFO Joseph H. Iv Griffith sold 5,000 shares of the company's stock in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $7.07, for a total value of $35,350.00. Following the completion of the transaction, the chief financial officer owned 97,930 shares of the company's stock, valued at $692,365.10. This represents a 4.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last ninety days, insiders sold 10,000 shares of company stock valued at $80,593. Corporate insiders own 23.70% of the company's stock.
Institutional Investors Weigh In On 908 Devices
Several large investors have recently modified their holdings of MASS. Bank of America Corp DE grew its stake in shares of 908 Devices by 190.9% in the 4th quarter. Bank of America Corp DE now owns 94,753 shares of the company's stock valued at $208,000 after purchasing an additional 62,179 shares during the period. Two Sigma Investments LP bought a new stake in shares of 908 Devices in the 4th quarter valued at approximately $42,000. FNY Investment Advisers LLC bought a new stake in shares of 908 Devices in the 1st quarter valued at approximately $338,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of 908 Devices in the 1st quarter valued at approximately $45,000. Finally, Bank of New York Mellon Corp grew its stake in shares of 908 Devices by 4.0% in the 1st quarter. Bank of New York Mellon Corp now owns 51,915 shares of the company's stock valued at $233,000 after purchasing an additional 1,985 shares during the period. 88.06% of the stock is currently owned by institutional investors.
908 Devices Company Profile
(
Get Free Report)
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider 908 Devices, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 908 Devices wasn't on the list.
While 908 Devices currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.